SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma gains on launching additional strengths for generic version of Revlimid in USA

10 Mar 2023 Evaluate

Natco Pharma is currently trading at Rs. 564.70, up by 4.45 points or 0.79% from its previous closing of Rs. 560.25 on the BSE.

The scrip opened at Rs. 568.35 and has touched a high and low of Rs. 568.40 and Rs. 559.55 respectively. So far 586 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 872.60 on 10-Mar-2022 and a 52 week low of Rs. 502.00 on 02-Feb-2023.

Last one week high and low of the scrip stood at Rs. 580.00 and Rs. 556.20 respectively. The current market cap of the company is Rs. 10227.77 crore.

The promoters holding in the company stood at 48.82%, while Institutions and Non-Institutions held 26.65% and 24.53% respectively.

Natco Pharma has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries.

With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1174.00 19.80 (1.72%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×